keyword
MENU ▼
Read by QxMD icon Read
search

secondary antiphospholipid antibody syndrome

keyword
https://www.readbyqxmd.com/read/27913550/prevention-of-thrombosis-in-antiphospholipid-syndrome
#1
Wendy Lim
Antiphospholipid syndrome (APS) is an acquired autoimmune condition characterized by thrombotic events, pregnancy morbidity, and laboratory evidence of antiphospholipid antibodies (aPL). Management of these patients includes the prevention of a first thrombotic episode in at-risk patients (primary prevention) and preventing recurrent thrombotic complications in patients with a history of thrombosis (secondary prevention). Assessment of thrombotic risk in these patients, balanced against estimated bleeding risks associated with antithrombotic therapy could assist clinicians in determining whether antithrombotic therapy is warranted...
December 2, 2016: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/27866581/thrombosis-hypercoagulable-states-and-anticoagulants
#2
REVIEW
Marie A Hollenhorst, Elisabeth M Battinelli
Patients with derangements of secondary hemostasis resulting from inherited or acquired thrombophilias are at increased risk of venous thromboemboli (VTE). Evaluation of a patient with suspected VTE proceeds via evidence-based algorithms that involve computing a pretest probability based on the history and physical examination; this guides subsequent work-up, which can include D dimer and/or imaging. Testing for hypercoagulable disorders should be pursued only in patients with VTE with an increased risk for an underlying thrombophilia...
December 2016: Primary Care
https://www.readbyqxmd.com/read/27776934/the-antiphospholipid-syndrome-in-patients-with-systemic-lupus-erythematosus
#3
Guillermo J Pons-Estel, Laura Andreoli, Francesco Scanzi, Ricard Cervera, Angela Tincani
The antiphospholipid syndrome (APS) is an autoimmune disease characterized by the occurrence of venous and/or arterial thrombosis and pregnancy morbidity in the presence of pathogenic autoantibodies known as antiphospholipid antibodies (aPL). APS may be associated with other diseases, mainly systemic lupus erythematosus (SLE). The presence or absence of SLE might modify the clinical or serological expression of APS. Apart from the classical manifestations, APS patients with associated SLE more frequently display a clinical profile with arthralgias, arthritis, autoimmune hemolytic anemia, livedo reticularis, epilepsy, glomerular thrombosis, and myocardial infarction...
October 21, 2016: Journal of Autoimmunity
https://www.readbyqxmd.com/read/27759698/occlusive-nonvasculitic-vasculopathy-a-review
#4
Mar Llamas-Velasco, Victoria Alegría, Ángel Santos-Briz, Lorenzo Cerroni, Heinz Kutzner, Luis Requena
We review the most characteristic clinical and histopathologic findings of the cutaneous manifestations of the occlusive nonvasculitic vasculopathic disorders. Clinically, most of these conditions are characterized by retiform purpura. Histopathologic findings consist of occlusion of the vessel lumina with no vasculitis. Different disorders may produce nonvasculitic occlusive vasculopathy in cutaneous blood and lymphatic vessels, including embolization due to cholesterol and oxalate emboli, cutaneous intravascular metastasis from visceral malignancies, atrial myxomas, intravascular angiosarcoma, intralymphatic histiocytosis, intravascular lymphomas, endocarditis, crystal globulin vasculopathy, hypereosinophilic syndrome, and foreign material...
October 18, 2016: American Journal of Dermatopathology
https://www.readbyqxmd.com/read/27694537/microangiopathic-antiphospholipid-antibody-associated-syndrome-in-a-pregnant-lady
#5
G S Kew, J Cho, A Lateef
We describe a gravid 37-year-old Chinese lady with known triple positive primary antiphospholipid syndrome with previous recurrent deep vein thrombosis and early spontaneous miscarriages. She was managed with low-molecular weight heparin, aspirin, hydroxychloroquine, prednisolone and monthly intravenous immunoglobulin.She presented with recurrent per-vaginal bleeding at 22 weeks of gestation and was found to have abruptio placentae. Anti-coagulation was held off. She subsequently delivered a stillborn at 24 weeks and anti-coagulation was restarted...
October 1, 2016: Lupus
https://www.readbyqxmd.com/read/27638930/annals-express-antiphospholipid-and-antioangiogenic-activity-in-women-with-recurrent-miscarriage-and-antiphospholipid-syndrome
#6
H Fabián Pelusa, Eleonora Pezzarini, Cecilia Basiglio, Jorge Musuruana, Mariela Bearzotti, María José Svetaz, Stella Maris Daniele, Hebe Bottai, Sandra M M Arriaga
BACKGROUND: Antiphospholipid syndrome (APS) is an autoimmune disease characterized by thrombosis, fetal losses and thrombocytopenia associated to antiphospholipid (APL) antibodies (Abs). They are directed to phospholipids, such as cardiolipins (a-cardiolipin, ACA) and lupus anticoagulant (LA), or to complexes formed by phospholipids and protein cofactors, such as β2 glycoprotein 1 (a-β2GP1) and annexin V (a-annexin V). These auto Abs may be considered as a family of Abs involved in thrombotic events and APL activity...
September 16, 2016: Annals of Clinical Biochemistry
https://www.readbyqxmd.com/read/27562033/lipid-peroxidation-as-risk-factor-for-endothelial-dysfunction-in-antiphospholipid-syndrome-patients
#7
Natasa Stanisavljevic, L Stojanovich, D Marisavljevic, A Djokovic, V Dopsaj, J Kotur-Stevuljevic, J Martinovic, L Memon, S Radovanovic, B Todic, D Lisulov
The aim of this study was to evaluate oxidative stress markers and it relations to endothelial damage as risk factor for thrombosis in patients with primary (PAPS) and secondary (SAPS) antiphospholipid syndrome (APS) in correlation to traditional risk factors. Flow-mediated (FMD) and nitroglycerine (NMD)-induced dilation of the brachial artery were studied in 140 APS patients (90 PAPS, 50 SAPS) and 40 controls matched by age, sex, and conventional risk factors for atherosclerosis. Markers of oxidative stress, lipid hydroperoxydes (LOOH), advanced oxidation protein products (AOPP), total sulfhydryl groups (tSHG), and paraoxonase 1 activity (PON1) were determined by spectrophotometric method...
October 2016: Clinical Rheumatology
https://www.readbyqxmd.com/read/27548039/severe-bilateral-retinal-vascular-occlusion-as-first-presentation-of-systemic-lupus-erythematosus-and-antiphospholipid-syndrome
#8
Philip Storey, Anna Ter-Zakarian, Narsing Rao, Damien Rodger
PURPOSE: To describe a patient with undiagnosed systemic lupus erythematosus and secondary antiphospholipid syndrome presenting with bilateral severe retinal vaso-occlusion on first presentation. METHODS: Retrospective case report. A 42-year-old Hispanic female with no medical history presented with 2 weeks of bilateral decreased vision. RESULTS: At initial presentation, the patient's best-corrected visual acuity was 2 ft/200 and 20/400 in the right and left eyes, respectively...
August 19, 2016: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/27384760/lymphocytopenia-is-associated-with-anti-beta-2-glycoprotein-1-in-patients-with-systemic-lupus-erythematosus
#9
Thelma Skare, Eduardo Augusto Borba, Shirley Ramos Utiyama, Renato Nisihara
BACKGROUND: Anti B2-Glicoprotein 1 (B2-GPI) is an antiphospholipid antibody that may be present in primary or secondary antiphospholipid syndrome (APS). Systemic Lupus erythematosus (SLE) is the main disease associated with secondary APS. OBJECTIVE: To study the prevalence of anti B2-GPI in SLE patients. METHODS: Anti B2-GPI (IgM/IgG) was studied by ELISA in 88 patients with SLE of both genders; 18.6% of which with secondary APS. Charts were reviewed for clinical and serological profile...
June 22, 2016: Acta Reumatológica Portuguesa
https://www.readbyqxmd.com/read/27334977/the-antiphospholipid-syndrome-from-pathophysiology-to-treatment
#10
Simone Negrini, Fabrizio Pappalardo, Giuseppe Murdaca, Francesco Indiveri, Francesco Puppo
Antiphospholipid antibody syndrome (APS) is an autoimmune acquired thrombophilia characterized by recurrent thrombosis and pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). APS can be primary, if it occurs in the absence of any underlying disease, or secondary, if it is associated with another autoimmune disorder, most commonly systemic lupus erythematosus. The exact pathogenetic mechanism of APS is unknown, but different, not mutually exclusive, models have been proposed to explain how anti-PL autoantibodies might lead to thrombosis and pregnancy morbidity...
June 22, 2016: Clinical and Experimental Medicine
https://www.readbyqxmd.com/read/27307185/adrenal-gland-abnormalities-detected-by-magnetic-resonance-imaging-in-patients-with-antiphospholipid-syndrome
#11
A A Shahin, S M El Desouky, M Y Awadallah, D E Megahed
BACKGROUND: Adrenal infarction is a rare complication of antiphospholipid syndrome (APS). OBJECTIVES: The purpose of the current study is to detect and study the magnetic resonance imaging (MRI) findings of adrenal glands in APS patients. MATERIALS AND METHODS: In a cross-sectional study, the data of 20 patients with primary or secondary APS were compared to 20 SLE patients without antiphospholipid antibody (aPL) syndrome (controls). MRI of the abdomen showing the adrenal glands was performed...
June 15, 2016: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/27275267/systemic-lupus-erythematosus-and-secondary-antiphospholipid-syndrome-after-thymectomy-for-myasthenia-gravis-a-case-report
#12
Rada Miskovic, Aleksandra Plavsic, Aleksandra Peric-Popadic, Sanvila Raskovic, Mirjana Bogic
INTRODUCTION: Systemic lupus erythematosus (SLE) and myasthenia gravis (MG) are autoimmune diseases that show some similarities: a higher incidence in young women, relapsing-remitting course and positive anti-nuclear antibodies (ANA). However, they are two different clinical syndromes, which can coexist or precede each other. Thymectomy is a therapeutic option for patients with severe MG or thymoma. There are many cases of SLE after thymectomy described in the literature, so the question arises whether thymectomy predisposes patients to SLE and what are imunopathogenetic mechanisms behind this process...
September 15, 2015: Open Access Macedonian Journal of Medical Sciences
https://www.readbyqxmd.com/read/27263620/lupus-anticoagulant-and-anticardiolipin-antibodies-in-sle-with-secondary-antiphospholipid-antibody-syndrome
#13
Shveta Garg, Annamma Kurien
Thirty patients with systemic lupus erythematosus (SLE) and suspected secondary antiphospholipid antibody syndrome (APLAS) were evaluated in the study based on their clinical manifestations. The aim was to study the prevalence of various antiphospholipid antibodies, compare the tests used for their detection and to find a correlation between clinical and laboratory parameters. Coagulation tests used were activated partial thromboplastin time, dilute Russell viper venom time and kaolin clotting time and the results were analyzed statistically...
June 5, 2007: Turkish Journal of Haematology: Official Journal of Turkish Society of Haematology
https://www.readbyqxmd.com/read/27252269/autoantibodies-to-domain-1-of-beta-2-glycoprotein-i-determined-using-a-novel-chemiluminescence-immunoassay-demonstrate-association-with-thrombosis-in-patients-with-antiphospholipid-syndrome
#14
M Mahler, R Albesa, N Zohoury, M L Bertolaccini, O Ateka-Barrutia, J L Rodriguez-Garcia, G L Norman, M Khamashta
INTRODUCTION: Antibodies to the domain 1 of beta 2 glycoprotein I (β2GPI-D1) have been suggested as a risk marker for thrombosis in patients with the antiphospholipid syndrome (APS). This cross-sectional study aimed to analyze the clinical utility of a novel chemiluminescence assay for the detection of anti-β2GPI-D1 antibodies. PATIENTS AND METHODS: Sera collected from patients with primary or secondary APS (n = 106; 72 with and 34 without history of thrombosis) and controls (n = 272) were tested for anti-β2GPI-D1 IgG by chemiluminescence assay (QUANTA Flash) and by two anti-β2GPI IgG assays (QUANTA Lite and QUANTA Flash β2GPI IgG)...
July 2016: Lupus
https://www.readbyqxmd.com/read/27225212/hughes-syndrome-and-epilepsy-when-to-test-for-antiphospholipid-antibodies
#15
M H A Noureldine, G Harifi, A Berjawi, A A Haydar, M Nader, R Elnawar, A Sweid, J Al Saleh, M A Khamashta, I Uthman
Epilepsy and seizures are reported among the neurological manifestations of antiphospholipid syndrome (APS) at a prevalence rate of approximately 8%, which is nearly 10 times the prevalence of epilepsy in the general population. The association of seizures with antiphospholipid antibodies (aPL) is even more significant in the presence of systemic lupus erythematosus (SLE). In this review, we discuss the epidemiological, pathophysiological, laboratory, clinical, and radiological aspects of this association, and derive suggestions on when to consider testing for aPL in epileptic patients and how to manage seizures secondary to APS based on literature data...
May 25, 2016: Lupus
https://www.readbyqxmd.com/read/27209064/antiphospholipid-antibodies-detected-by-line-immunoassay-differentiate-among-patients-with-antiphospholipid-syndrome-with-infections-and-asymptomatic-carriers
#16
Dirk Roggenbuck, Maria Orietta Borghi, Valentina Somma, Thomas Büttner, Peter Schierack, Katja Hanack, Claudia Grossi, Caterina Bodio, Paolo Macor, Philipp von Landenberg, Francesco Boccellato, Michael Mahler, Pier Luigi Meroni
BACKGROUND: Antiphospholipid antibodies (aPL) can be detected in asymptomatic carriers and infectious patients. The aim was to investigate whether a novel line immunoassay (LIA) differentiates between antiphospholipid syndrome (APS) and asymptomatic aPL+ carriers or patients with infectious diseases (infectious diseases controls (IDC)). METHODS: Sixty-one patients with APS (56 primary, 22/56 with obstetric events only, and 5 secondary), 146 controls including 24 aPL+ asymptomatic carriers and 73 IDC were tested on a novel hydrophobic solid phase coated with cardiolipin (CL), phosphatic acid, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, beta2-glycoprotein I (β2GPI), prothrombin, and annexin V...
May 21, 2016: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/27198137/renal-involvement-in-primary-antiphospholipid-syndrome
#17
REVIEW
Carmelita Marcantoni, Carmela Emmanuele, Francesco Scolari
Antiphospholipid syndrome is an autoimmune disorder characterized by recurrent venous or arterial thrombosis and/or pregnancy-related problems associated with persistently elevated levels of antiphospholipid antibodies. The kidney is a major target organ in both primary and secondary antiphospholipid syndrome. This review describes several aspects of the renal involvement in the primary form of the syndrome, in particular the histological pattern of the so-called antiphospholipid syndrome nephropathy (APSN)...
August 2016: Journal of Nephrology
https://www.readbyqxmd.com/read/27068596/antiphospholipid-syndrome-with-subsequent-chronic-discoid-lupus-erythematosus-a-case-report
#18
Rosanna Satta, Paola Marongiu, Francesca Cottoni
Antiphospholipid syndrome is an immune-mediated acquired disorder characterized by vein and/or artery thromboses and obstetrical complications associated with the presence of antiphospholipid antibodies in the blood. aPL include anticardiolipin antibodies (aCL), antiβ2glycoproteinI (antiβ2GPI), and lupus anticoagulant (LAC). A primitive idiopathic form and a secondary form of APS are recognized. The latter, observed mostly in patients affected by systemic lupus erythmatosus (SLE), has been described in numerous other autoimmune diseases...
April 2016: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/27032789/prevention-of-recurrent-thrombosis-in-antiphospholipid-syndrome-different-from-the-general-population
#19
REVIEW
Kimberly Janet Legault, Amaia Ugarte, Mark Andrew Crowther, Guillermo Ruiz-Irastorza
Antiphospholipid syndrome (APS) is characterized by arterial and/or venous thrombosis with or without pregnancy morbidity in the presence of autoantibodies targeting proteins that associate with membrane phospholipids, termed "antiphospholipid antibodies" (aPL). Management of arterial and venous thromboses shares some similarities with management of arterial and venous thromboses in the general population; however, there are key differences. The majority of studies addressing management of thrombotic APS focus on secondary prevention...
May 2016: Current Rheumatology Reports
https://www.readbyqxmd.com/read/27015221/impact-of-antiphospholipid-syndrome-and-or-systemic-lupus-erythematosus-on-the-long-term-adverse-cardiovascular-outcomes-in-patients-after-percutaneous-coronary-intervention-a-systematic-review-and-meta-analysis
#20
REVIEW
Pravesh Kumar Bundhun, Kamini Devi Boodhoo, Man-Yun Long, Meng-Hua Chen
Antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) are 2 rare autoimmune disorders which commonly affect women. Several previous studies showed APS to have been evolved from SLE. Secondary APS often coexists with SLE. One common feature relating these 2 diseases are the antiphospholipid antibodies, which are found in most of the patients with APS and in approximately 30% to 40% of patients with SLE, among which, about 10% develop APS. The leading cause of death in these patients is from cardiovascular disease due to accelerated atherosclerosis, which often progresses more rapidly, compared with the general population...
March 2016: Medicine (Baltimore)
keyword
keyword
116552
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"